Skip to main content

Table 1 Raw values used for analyses

From: A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding

  

Incidence

Mort.

US Gov't

YLL (thousands)

WHO

DALY (thousands)

Medicare Spend$ (millions)

National spend $ (billions)

Lost

prod. (billions)

NCI Funding (millions)

AYLL

YLLPI

Bladder

Blad

70530

14680

154.4

128.7

1023

3.466

1.977

22.6

10.52

2.19

Brain, ONS

Br/cns

22020

13140

290.8

 

293

3.715

5.851

193.1

22.13

13.21

Breast

Breast

209060

40230

761.3

612.5

1375

13.886

10.879

631.2

18.92

3.64

Cervix

Cerv

12200

4210

104.7

114.1

73

1.425

1.808

76.5

24.87

8.58

Colon/rectum

Co/rec

142570

51370

764.6

542.1

3101

12.155

12.802

270.4

14.88

5.36

Esophogus

Esoph

16640

14500

214.2

122

386

1.071

---

30.5

14.77

12.87

Hogkin lymph.

H lym

8490

1320

29.8

288.7**

1350*

10.168*

0.829

14.6

22.58

3.51

Kidney

Kidney

58240

13040

195.7

---

685

3.058

3.633

90.0

15.01

3.36

Leukemia

leuk

43050

21840

355.2

210.5

695

4.507

5.880

295.8

16.26

8.25

Liver

Liver

24120

18910

292.2

137.8

278

---

4.638

72.6

15.45

12.11

Lung

Lung

222520

157300

2369

1247.6

4238

10.315

38.953

281.9

15.06

10.65

Myeloma

Myel

20180

10650

148.1

**

---

---

---

48.5

13.91

7.34

NH Lymphoma

NHL

65540

20210

292.4

**

*

*

5.755

122.4

14.47

4.46

Oral,pharnyx

Oral

36540

7880

138

85.4

---

---

---

13.9

17.51

3.78

Ovary

Ovary

21880

13850

248.8

145

507

4.379

2.945

112.3

17.96

11.37

Pancreas

Panc

43140

36800

498.4

237.7

771

1.884

7.058

97.1

13.54

11.55

Prostate

Pros

217730

32050

267.4

225

2294

9.862

3.538

300.5

8.34

1.23

Melanoma (skin)

Melo

68130

8700

150.7

120.6

181

1.906

3.298

102.3

17.32

2.21

Stomach

Stom

21000

10570

176

106.9

624

1.550

3.454

14.5

16.65

8.38

Testes

Test

8480

350

11.8

---

---

---

0.472

6.3

33.71

1.39

Uterus

Uter

43470

7950

122.8

75.5

340

2.330

1.101

14.2

15.45

2.82

  1. Incidence, mortality, YLL, three measures of economic cost (Medicare payments, overall medical spending, and lost productivity), research funding by the NCI and calculated values for AYLL and YLLPI using data from the table for the 21 cancers for which we had sufficient data. The symbol --- indicates that data for those values were not available, * indicates that for Medicare and National expenditure cost estimations the categories "Hodgkin's lymphoma" and "non-Hodgkin's lymphoma" were combined in those reports, ** indicates that for for World Health Organization (WHO) DALY estimates the categories "Hodgkin's lymphoma", "non-Hodgkin's lymphoma" and "myeloma" were combined in those reports.